Celecoxib, a COX2 inhibitor in association with adoptive therapy, enhances the antitumor effect of the vaccinotherapy with an increased survival rate, linked to the increased cytotoxicity of T cells and the decreased amounts of tumor-associated IDO [147]. The gene discussed is IDO1; the disease is neoplasm.